HGSI
Human Genome announces collaboration with Novartis for development and commercialization of Albuferon (10.19 ) : Co announces an exclusive worldwide licensing agreement with Novartis (NVS) for the development and commercialization of Albuferon for chronic hepatitis C and all other uses. Under the agreement, HGS and Novartis will co-commercialize Albuferon in the U.S., and will share U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization outside the U.S. and will pay HGS a royalty on those sales. HGS and Novartis will share equally in clinical development costs. HGS will receive an upfront fee of $45 mln. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 mln, including $47.5 mln when the first patient is dosed in a Phase 3 clinical trial. HGS will have primary responsibility for the bulk manufacture of Albuferon.
2- حبيب الشعب GOOG
Human Genome announces collaboration with Novartis for development and commercialization of Albuferon (10.19 ) : Co announces an exclusive worldwide licensing agreement with Novartis (NVS) for the development and commercialization of Albuferon for chronic hepatitis C and all other uses. Under the agreement, HGS and Novartis will co-commercialize Albuferon in the U.S., and will share U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization outside the U.S. and will pay HGS a royalty on those sales. HGS and Novartis will share equally in clinical development costs. HGS will receive an upfront fee of $45 mln. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 mln, including $47.5 mln when the first patient is dosed in a Phase 3 clinical trial. HGS will have primary responsibility for the bulk manufacture of Albuferon.
2- حبيب الشعب GOOG
